Achiko Valuation
Is ACHI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ACHI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ACHI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ACHI's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACHI?
Key metric: As ACHI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ACHI's PS Ratio? | |
|---|---|
| PS Ratio | 2.6x |
| Sales | US$24.60k |
| Market Cap | US$64.40k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 191.8x |
| Enterprise Value/EBITDA | -0.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ACHI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.9x | ||
OBSN ObsEva | 0.008x | n/a | CHF 140.6k |
SPEX Spexis | 5.7x | n/a | CHF 3.4m |
ADXN Addex Therapeutics | 9.4x | 44.2% | CHF 5.6m |
HSTO.Q Histogen | 4.5x | n/a | US$85.4k |
ACHI Achiko | 2.6x | n/a | CHF 58.1k |
Price-To-Sales vs Peers: ACHI is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (4x).
Price to Sales Ratio vs Industry
How does ACHI's PS Ratio compare vs other companies in the European Biotechs Industry?
| 38 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 38 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ACHI is good value based on its Price-To-Sales Ratio (2.6x) compared to the European Biotechs industry average (8x).
Price to Sales Ratio vs Fair Ratio
What is ACHI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ACHI's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Gerresheimer
€2.6b
Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.
GXI
€75.60
7D
0%
1Y
0%
Roche Holding
CHF 204.3b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
ROG
CHF 254.30
7D
-0.6%
1Y
6.5%
Cosmo Pharmaceuticals
CHF 1.0b
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 62.80
7D
-1.3%
1Y
58.4%